Medical AI Alliance
← Company Index
Biotech & Drug DiscoveryKOSDAQ 222980139 approvals8 trials

Mcnulty Korea Co., Ltd

Official website

Founded in 1997 and listed on KOSDAQ in 2015, Mcnulty Korea produces coffee under its Mcnulty brand with pharma and health food affiliates.

As of 2026-10-10, Mcnulty Korea Co., Ltd has 1 Korean MFDS device approval, 138 Korean MFDS drug approvals on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Mcnulty Korea Co., Ltd was founded in 1997 and listed on KOSDAQ in 2015, operating a vertically integrated coffee business spanning green bean import through roasted coffee production. Under its Mcnulty brand, the company produces roasted coffee, freeze-dried (FD) instant coffee, and ready-to-drink coffee beverages, while affiliates Mcnulty Pharma produces prescription drugs including Ultramag Tab and Mcnulty Bio produces health functional foods including Easy Protein. The coffee business processes purchased green beans through roasting into multiple product lines, the pharmaceutical business supplies products to multiple pharmaceutical companies on a consignment sales basis, and the health functional food business manufactures customized products by client.

Products & technology

  • Roasted coffee, etc.Coffee products (Mcnulty brand)
  • Ultramag Tab, etc.Prescription pharmaceuticals, etc.
  • Easy Protein, etc.Health functional foods, etc.

Regulatory approvals

data.go.kr

138 Korean MFDS drug approvals · 2003–2026 / 1 Korean MFDS device approvals · 2023

  • MFDS drugSubsidiary: 맥널티제약(주)TasMac Tab.2026-03-04
    Drug · OTC · Notification202600649
  • MFDS drugSubsidiary: 맥널티제약(주)CalDmax Soft Cap.2025-11-27
    Drug · OTC · Notification202503096
  • MFDS drugSubsidiary: 맥널티제약(주)Chemipad SR Tab. 150mg2025-08-28
    Drug · Prescription · Approval202502262
  • MFDS drugSubsidiary: 맥널티제약(주)Power Tension Sol.2024-12-18
    Drug · OTC · Notification202403010
  • MFDS drugSubsidiary: 맥널티제약(주)Gingkomac Tab. 240mg2024-07-29
    Drug · OTC · Notification202401830
  • MFDS drugSubsidiary: 맥널티제약(주)ColMac-Cold Syrup2024-02-06
    Drug · OTC · Notification202400274
  • MFDS drugSubsidiary: 맥널티제약(주)Centigold-M cap.2023-11-15
    Drug · OTC · Notification202303153
  • MFDSSubsidiary: 맥널티제약(주)Graft/prosthesis, biomaterial2023-10-04
    Product approval · Class 4제허 23-952 호
  • MFDS drugSubsidiary: 맥널티제약(주)ColMac-Nose Syrup2023-09-04
    Drug · OTC · Notification202302626
  • MFDS drugSubsidiary: 맥널티제약(주)ColMac-Cold SyrupRevoked2023-08-21
    Drug · OTC · Notification202302470
  • MFDS drugSubsidiary: 맥널티제약(주)Centigold cap.2023-07-06
    Drug · OTC · Notification202302071
  • MFDS drugSubsidiary: 맥널티제약(주)GlymejaQ Tab. 50/500mg2023-06-27
    Drug · Prescription · Approval202301973
Show 68 more
  • MFDS drugSubsidiary: 맥널티제약(주)GlymejaQ Tab. 50/850mg2023-06-27
    Drug · Prescription · Approval202301974
  • MFDS drugSubsidiary: 맥널티제약(주)GlymejaQ Tab.50/1000mg2023-06-27
    Drug · Prescription · Approval202301975
  • MFDS drugSubsidiary: 맥널티제약(주)GlyjanuQ Tab. 100mg2023-06-26
    Drug · Prescription · Approval202301940
  • MFDS drugSubsidiary: 맥널티제약(주)GlyjanuQ Tab. 50mg2023-06-26
    Drug · Prescription · Approval202301941
  • MFDS drugSubsidiary: 맥널티제약(주)Maxel-D Tab.2023-04-14
    Drug · OTC · Notification202301242
  • MFDS drugSubsidiary: 맥널티제약(주)Pepto-Mus Suspension2023-04-11
    Drug · OTC · Approval202301183
  • MFDS drugSubsidiary: 맥널티제약(주)Dapaglisita-M Tab. 10/100mg2023-01-30
    Drug · Prescription · Approval202300387
  • MFDS drugSubsidiary: 맥널티제약(주)M-dapa Tab.5mg2022-12-29
    Drug · Prescription · Approval202204688
  • MFDS drugSubsidiary: 맥널티제약(주)Tritan Tab. 150mg2022-09-06
    Drug · OTC · Notification202203495
  • MFDS drugSubsidiary: 맥널티제약(주)M-rodin Solution(L-Carnitine)2022-09-06
    Drug · OTC · Notification202203501
  • MFDS drugSubsidiary: 맥널티제약(주)M-dapa Tab.10mg2022-08-31
    Drug · Prescription · Approval202203469
  • MFDS drugSubsidiary: 맥널티제약(주)M-naproxen Soft Cap.2022-05-24
    Drug · OTC · Notification202202195
  • MFDS drugSubsidiary: 맥널티제약(주)Maxelen-BZ Tab.2022-02-18
    Drug · OTC · Notification202200765
  • MFDS drugSubsidiary: 맥널티제약(주)M-Vildagliptin Tab. 50mg2022-01-04
    Drug · Prescription · Approval202200087
  • MFDS drugSubsidiary: 맥널티제약(주)Hepamin Granule (for export)2021-12-20
    Drug · Prescription · Notification202108037
  • MFDS drugSubsidiary: 맥널티제약(주)Sinbia Syrup2021-08-06
    Drug · OTC · Notification202105771
  • MFDS drugSubsidiary: 맥널티제약(주)Transamin Cap. 250mg2020-10-26
    Drug · Prescription · Notification202007329
  • MFDS drugSubsidiary: 맥널티제약(주)Famowitun Tab. 10mg2020-10-07
    Drug · OTC · Notification202006820
  • MFDS drugSubsidiary: 맥널티제약(주)Damopanten Tab. 100mg2020-09-29
    Drug · OTC · Notification202006701
  • MFDS drugSubsidiary: 맥널티제약(주)Rosuva-M Tab. 5mg2020-07-21
    Drug · Prescription · Approval202005250
  • MFDS drugSubsidiary: 맥널티제약(주)Maxelen-D Tab.2020-06-22
    Drug · OTC · Notification202004542
  • MFDS drugSubsidiary: 맥널티제약(주)Otimon Tab.2020-05-29
    Drug · Prescription · Approval202004013
  • MFDS drugSubsidiary: 맥널티제약(주)O-three Soft Cap.Revoked2020-05-29
    Drug · Prescription · Approval202004110
  • MFDS drugSubsidiary: 맥널티제약(주)Anadmac Cap. 1mgRevoked2020-04-27
    Drug · Prescription · Approval202003050
  • MFDS drugSubsidiary: 맥널티제약(주)Anadmac Cap. 0.5mgRevoked2020-04-27
    Drug · Prescription · Approval202003051
  • MFDS drugSubsidiary: 맥널티제약(주)Azathimac Tab. 50mgRevoked2020-04-27
    Drug · Prescription · Approval202003057
  • MFDS drugSubsidiary: 맥널티제약(주)Azathimac Tab. 25mgRevoked2020-04-27
    Drug · Prescription · Approval202003058
  • MFDS drugSubsidiary: 맥널티제약(주)Rosuva-L Tab. 10mg2020-04-16
    Drug · Prescription · Approval202002664
  • MFDS drugSubsidiary: 맥널티제약(주)Rosuva-L Tab. 20mg2020-04-16
    Drug · Prescription · Approval202002666
  • MFDS drugSubsidiary: 맥널티제약(주)Pla-M Tab.2020-03-27
    Drug · Prescription · Approval202002145
  • MFDS drugSubsidiary: 맥널티제약(주)Ricalbon Tab. 35mg2020-01-28
    Drug · Prescription · Approval202000412
  • MFDS drugSubsidiary: 맥널티제약(주)Rabera-M Tab. 20mg2019-11-26
    Drug · Prescription · Approval201908081
  • MFDS drugSubsidiary: 맥널티제약(주)Proamo Tab. 1mg2019-11-20
    Drug · Prescription · Approval201908019
  • MFDS drugSubsidiary: 맥널티제약(주)Donepeon Tab. 5mg2019-09-30
    Drug · Prescription · Approval201906920
  • MFDS drugSubsidiary: 맥널티제약(주)Aclaon Duo Tab. 500mg (7:1)Revoked2019-09-30
    Drug · Prescription · Approval201906997
  • MFDS drugSubsidiary: 맥널티제약(주)MRT Oct Tab. 480mg2019-09-27
    Drug · Prescription · Approval201906897
  • MFDS drugSubsidiary: 맥널티제약(주)Donepeon Tab. 10mg2019-09-25
    Drug · Prescription · Approval201906830
  • MFDS drugSubsidiary: 맥널티제약(주)Arion Tab. 10mg2019-09-18
    Drug · Prescription · Approval201906510
  • MFDS drugSubsidiary: 맥널티제약(주)Aclaon Tab. 625mg (4:1)2019-09-11
    Drug · Prescription · Approval201906436
  • MFDS drugSubsidiary: 맥널티제약(주)Eldo-S Cap.2019-08-27
    Drug · OTC · Notification201906089
  • MFDS drugSubsidiary: 맥널티제약(주)Aclaon Tab. 375mg (2:1)2019-08-27
    Drug · Prescription · Approval201906090
  • MFDS drugSubsidiary: 맥널티제약(주)Arion Tab. 20mgRevoked2019-07-12
    Drug · Prescription · Approval201904707
  • MFDS drugSubsidiary: 맥널티제약(주)Pactamine D3 Tab. 25000IU2019-07-09
    Drug · Prescription · Notification201904637
  • MFDS drugSubsidiary: 맥널티제약(주)Macsevikar Tab. 5/20mg2019-07-02
    Drug · Prescription · Approval201904506
  • MFDS drugSubsidiary: 맥널티제약(주)Duo M Tab. 40/10mg2019-06-21
    Drug · Prescription · Approval201904300
  • MFDS drugSubsidiary: 맥널티제약(주)Duo M Tab. 80/5mg2019-06-21
    Drug · Prescription · Approval201904301
  • MFDS drugSubsidiary: 맥널티제약(주)Duo M Tab. 40/5mg2019-06-21
    Drug · Prescription · Approval201904302
  • MFDS drugSubsidiary: 맥널티제약(주)Dutaon Soft Cap. 0.5mg2019-04-25
    Drug · Prescription · Approval201902598
  • MFDS drugSubsidiary: 맥널티제약(주)Promoa Tab. 5mg2019-04-16
    Drug · Prescription · Approval201902332
  • MFDS drugSubsidiary: 맥널티제약(주)Macsevikar Tab. 10/40mg2019-04-15
    Drug · Prescription · Approval201902308
  • MFDS drugSubsidiary: 맥널티제약(주)Eldo-S Tab.2019-04-11
    Drug · OTC · Notification201902226
  • MFDS drugSubsidiary: 맥널티제약(주)Macsevikar Tab. 5/40mg2019-04-08
    Drug · Prescription · Approval201902139
  • MFDS drugSubsidiary: 맥널티제약(주)Rabera-M Tab. 10mg2019-03-27
    Drug · Prescription · Approval201901830
  • MFDS drugSubsidiary: 맥널티제약(주)Mcnulty Meropenem Inj. 1gRevoked2019-03-20
    Drug · Prescription · Approval201901687
  • MFDS drugSubsidiary: 맥널티제약(주)Acytein Cap. 200mgRevoked2019-03-20
    Drug · OTC · Notification201901688
  • MFDS drugSubsidiary: 맥널티제약(주)Mcnulty Meropenem Inj. 500mgRevoked2019-03-14
    Drug · Prescription · Approval201901565
  • MFDS drugSubsidiary: 맥널티제약(주)NEXION.Tab 40mg2019-01-24
    Drug · Prescription · Approval201900623
  • MFDS drugSubsidiary: 맥널티제약(주)Mosaprion Tab.2019-01-22
    Drug · Prescription · Approval201900301
  • MFDS drugSubsidiary: 맥널티제약(주)Flulazole Cap.2018-11-22
    Drug · Prescription · Approval201804646
  • MFDS drugSubsidiary: 맥널티제약(주)NEXION.Tab 20mg2018-10-31
    Drug · Prescription · Approval201804329
  • MFDS drugSubsidiary: 맥널티제약(주)Easypact Solution2018-09-27
    Drug · OTC · Approval201803803
  • MFDS drugSubsidiary: 맥널티제약(주)ACLAON Duo Syr2018-08-27
    Drug · Prescription · Notification201803477
  • MFDS drugSubsidiary: 맥널티제약(주)Lipitan Tab. 20mg2018-07-30
    Drug · Prescription · Approval201803145
  • MFDS drugSubsidiary: 맥널티제약(주)Nicowinner Tab. 0.5mg2018-06-15
    Drug · Prescription · Approval201802479
  • MFDS drugSubsidiary: 맥널티제약(주)Nicowinner Tab. 1mg2018-06-15
    Drug · Prescription · Approval201802480
  • MFDS drugSubsidiary: 맥널티제약(주)McClean Tab. 1mgRevoked2018-06-15
    Drug · Prescription · Approval201802495
  • MFDS drugSubsidiary: 맥널티제약(주)McClean Tab. 0.5mgRevoked2018-06-15
    Drug · Prescription · Approval201802496
  • MFDS drugSubsidiary: 맥널티제약(주)Zaltoren Tab.2018-01-11
    Drug · Prescription · Approval201800173

Showing the 80 most recent of 139 records.

Clinical trials

data.go.kr

8 MFDS clinical trial authorisations · 2012–2016 (Bioequivalence 8)

  • Bioequivalence베리맥정 10밀리그램(베포타스틴베실산염)2016-08-18

    2 trial sites

  • Bioequivalence메피정(메틸프레드니솔론)2015-12-03

    2 trial sites

  • Bioequivalence글리맥정(콜린알포세레이트)2015-11-19

    2 trial sites

  • Bioequivalence쎄르펜캡슐(세레콕시브)2015-11-02

    2 trial sites

  • Bioequivalence하이비스정2015-09-02

    2 trial sites

  • Bioequivalence오라맥정(에스오메프라졸마그네슘이수화물)2014-11-20

    2 trial sites

  • Bioequivalence맥널티비티스정(가칭)2012-11-05

    1 trial site

  • Bioequivalence맥널티비티스정(가칭) 50mg2012-11-05

    1 trial site

Key disclosures

KRX KIND via OpenDART

Patents

KIPRIS · applicant-matched
Show 6 more patents

AI reads

MAA server logs · IP-verified
37
Times AI engines pulled Mcnulty Korea Co., Ltd's records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

1
Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

36
Index crawls

Collected as raw material for future answers.

0
Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

10
live 0
Last 7 days
31
live 1
Last 30 days
37
live 1
All time
  • OpenAIChatGPT-Userlive1
  • OpenAIOAI-SearchBot31
  • PerplexityPerplexityBot2
  • AnthropicClaudeBot2
  • GoogleGoogleOther1

Measured since Aug 27, 2026 · 4 AI engines · last read Oct 9, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Mcnulty Korea Co., Ltd and every listed Korean medical, bio and AI company.

How to connect (MCP)
Not yet compiled: business overview · R&D. Send us materials and we will add them

Companies approved for the same productsBiotech & Drug Discovery

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

Hanmi Pharm. Co., Ltd.1 shared

KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).

HANS BIOMED CORPORATION1 shared

KOSDAQ-listed medical device company producing human tissue implants Bella Cell HD and SureFuse.

L&C BIO Co., Ltd1 shared

L&C BIO manufactures human tissue grafts across 11 tissue types, including the acellular dermal matrix MegaDerm, plus tissue-based medical devices.

BioPlus Co., Ltd1 shared

Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.

Hugel, Inc.1 shared

Hugel is a KOSDAQ-listed pharmaceutical/CDMO company making a botulinum toxin injectable and the hyaluronic acid filler The Chaeum.

DongBang Medical Co., Ltd.1 shared

KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.

Daehan Nupharm Co.,Ltd.1 shared

KOSDAQ-listed pharmaceutical company producing a diverse, low-volume portfolio of metabolic disease drugs, wellness injections, and veterinary medicines.

JETEMA Co.,Ltd.1 shared

Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.

HANALL BIOPHARMA CO.,LTD1 shared

KOSPI-listed pharma/biotech company co-developing the autoimmune biologics batoclimab and imeropruvate with partner Immunovant.

Hironic Co.,Ltd1 shared

KOSDAQ-listed medical device company producing HIFU devices DOUBLO/V-RO and the Synerjet non-invasive drug delivery system for aesthetic dermatology.

CELLUMED CO., LTD.1 shared

KOSDAQ-listed holding company making medical devices and biologics including bone graft rhBMP2 and knee implant TKR.

CAREGEN CO.,LTD.1 shared

CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics
Korea Exchange · DART
Business content
Compiled from disclosure filings
Approvals & clinical trials
Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures
KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials
ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials
DART corporate disclosure filings — annual
Publications
PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents
KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads
Our server logs, IP-verified every 6 hours
AI visibility
Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition